Ozempic has stormed the world, grossing billions and becoming a household name not only for controlling blood sugar but also for its dramatic weight-loss effect. But before it was a celebrity-favored fad, its beginnings were anything but glamorous. This medical wonder has its roots in an unexpected place: a toxic desert lizard with a remarkable talent for living on a few meals a year—the Gila monster.

The Gila monster (Heloderma suspectum), which inhabits the deserts of North America, is famous for its slow movements and highly toxic venom. Its bite is lethal enough to kill small animals and inflict extreme pain on humans. But lurking in this venom was a breakthrough that led to Ozempic. Researchers examining the venom of the Gila monster discovered that it consisted of a novel hormone that delays digestion and modulates blood glucose levels—an advantage that enables the lizard to get by on a meager diet.

Also Read: Ozempic Users Found To Age Back By More Than 3 Years, Finds New Trial; Peer Review Pending

In the early 21st century, endocrinologist Daniel Drucker asked for a hormone that mimicked the appetite-inhibiting and blood sugar-controlling action of human glucagon-like peptide-1 (GLP-1) yet would not be quickly broken down in the body. He was prompted by the research of scientists John Eng, Jean-Pierre Raufman, and John Pisano, who had cloned the proteins in Gila monster venom and found two similar in structure to human GLP-1.

Drucker and his colleagues at the University of Toronto obtained a Gila monster from the Utah Zoo breeding program to further study its distinctive biochemistry. Their work identified Exendin-4, a protein that closely resembled GLP-1 but persisted much longer in the blood. This discovery ultimately gave rise to synthetic GLP-1 agonists, transforming the treatment of type 2 diabetes and, more recently, obesity.

Though promising, it took decades before the discovery found its way into an FDA-approved drug. The initial GLP-1 agonist based on Gila monster venom was approved to treat diabetes in 2005. The two decades that followed saw the formulation of more advanced drugs such as semaglutide, which is the active component in Ozempic and its weight loss equivalent, Wegovy.

Also Read: What Is Ozempic Smell? Another Unusually Side Effect Your Weight-Loss Injection Might Come With

Now, millions depend on Ozempic to control diabetes and shed pounds, with demand so great that worldwide shortages have been reported. Its popularity has created a surge in off-label use, with social media spreading trends of dramatic weight loss among celebrities and influencers. But the tale of Ozempic is only one illustration of how nature's most toxic animals have led to life-saving medical breakthroughs.

Other Drugs that Came from Poisonous Animals

Ozempic is hardly the first life-saving medication to be developed from the animal world's toolkit of toxins. From the beginning of time, scientists have turned to nature to find answers to human illnesses, and in the process, have developed some of the most crucial medical advances.

One of the highest-selling medicines in the world, Lisinopril, has its roots in the Brazilian viper (Bothrops jararaca). The venom from the snake includes enzyme inhibitors that inhibit the blood of its prey from clotting so the venom can travel quickly. Researchers took this process and developed angiotensin-converting enzyme (ACE) inhibitors, which decrease blood pressure and are commonly used to treat heart disease and hypertension.

Far down in the ocean, the Caribbean sea sponge (Tectitethya crypta) has been secretly making substances that defend it from foreign DNA brought by predators and prey. Those unusual nucleosides were the foundation for cytarabine, a drug used to treat leukemia and non-Hodgkin's lymphoma through chemotherapy. This discovery reaffirmed the belief that even the most basic life forms can be the solution to revolutionary cures.

In a breathtaking illustration of the paradoxical position of nature in medicine, deathstalker scorpion venom (Leiurus quinquestriatus) brought about the solution to the treatment of brain tumors. A team led by oncologist Jim Olson found that a peptide found in the venom, chlorotoxin Cy5.5, attaches itself only to brain tumor cells and leaves healthy tissue intact. This resulted in the creation of Tozuleristide, a fluorescent tag that aids surgeons in precise identification and resection of cancerous tissue.

The popularity of Ozempic and other venom-based medications indicates the yet unutilized potential of the biochemistry of nature. From fungal-sourced antibiotics to animal-venom-derived painkillers, researchers are learning every day about the possibilities for leveraging the might of nature. Researchers now search for potential new treatments for neurological conditions, pain, and heart disease from the spider venom, cone snail toxin, and even the bat's saliva.

But these findings are also a harsh reminder that most of these species are threatened by habitat loss, climate change, and human use. The Gila monster, for instance, is threatened by land development and wildlife trade. Conservation of these species and their habitats is not only a conservation issue, it is an issue of future medical advancement as well.

Young adults who believe vaping is safer than smoking may be in for some surprising news. According to a new study, vape users presented reduced fitness and impaired blood vessel function similar to traditional cigarette smokers.

The research, published in the peer-reviewed journal ERJ Open Research, compared healthy adults aged 18 to 30 and found that both regular vapers and smokers had around 15% lower exercise capacity than people who had never smoked or vaped.

About The Study

The study involved 75 healthy young adults divided into three groups: non-smokers/non-vapers, cigarette smokers, and regular vapers who had never smoked.

Participants completed an incremental cycling test while researchers measured heart and lung function, oxygen activity, blood lactate levels, and overall vascular health.

Researchers also observed equally poor blood vessel function, reduced breathing efficiency during exercise, and early muscle fatigue in both those who vaped and smoked.

What Did The Study Find?

At peak exercise, both smokers and vapers showed significantly lower oxygen uptake and reached exhaustion sooner than non-users.

They also accumulated lactic acid more quickly, leading to greater breathlessness and increased leg discomfort during exercise. Ultrasound scans and blood tests further showed signs of impaired blood vessel function and inflammation.

Dr. Azmy Faisal, senior lecturer in cardiorespiratory physiology at Manchester Metropolitan University and lead author of the study, said, “In active, healthy young adults with normal lungs, both vapes and tobacco smoking led to worsened exercise capacity, shortness of breath, and intense leg fatigue.”

"Like smoking, our research indicates that vaping can lead to harmful changes to the blood vessels, lung efficiency during exercise, and approximately a 15% reduction in fitness compared to those who have never smoked or vaped," Faisal added.

Dr. Stamatoula Tsikrika of the European Respiratory Society commented on the findings, saying the growing popularity of vaping among young people who have never smoked is becoming an increasing public health concern.

Also read: How Smoking, Alcohol, And Vaping Are Quietly Hurting Women’s Fertility

"More and more young people who have never smoked are using vapes," Tsikrika said. "As the popularity of vaping continues to rise, so too do concerns that it is becoming normalised behaviour, functioning as a gateway to nicotine addiction and introducing serious health risks."

She noted that although e-cigarettes may contain fewer cancer-causing substances than conventional cigarettes, they can still lead to significant genetic changes.

"Vapes may contain lower levels of cancer-causing substances, but they can still trigger genetic changes such as DNA damage and inflammation, which are linked to increased lung cancer risk," Tsikrika said. "For people who have never smoked and are therefore not using vapes as a cessation method, the health consequences of vaping are becoming harder for policymakers and the tobacco industry to justify."

Also read: Friends Can Have A Big Impact On Vaping Habits, Study Suggests

Smoking Vs Vaping

The researchers, however, caution that the study does not suggest that vaping is equally harmful as smoking in every respect.

Traditional cigarettes still strongly remain linked to major disorders like cancer, chronic obstructive pulmonary disease (COPD), and many other life-threatening illnesses.

But the new study indicates that when it comes to cardiovascular fitness, breathing efficiency, lung function and blood vessel health in young adults, vaping may offer far less protection.

The U.S. government's Department of Health and Human Services (HHS) recently announced partnering with the Department of Veterans Affairs (VA) to fast-track the development of psychedelic-assisted therapies to treat veterans living with mental health issues like post-traumatic stress disorder (PTSD), depression, traumatic brain injury (TBI), and more.

After years of interest, 2026 has marked a major policy shift, with the White House, Congress, and the Department of Veterans Affairs (VA) all actively participating in accelerating research into treatments like psilocybin, MDMA, and ibogaine.

“America owes every veteran the best care our nation can provide,” said HHS Secretary Robert F. Kennedy, Jr. “We’re not going to wait while promising treatments sit on the sidelines. Thanks to President Trump’s leadership, HHS and the VA are working together to develop safe, FDA-approved innovations and transition them from research into care so veterans can access the treatments they deserve.”

The collaboration comes as a bipartisan group of lawmakers introduced a new bill in Congress that would require the U.S. Department of Defense to evaluate how ongoing psychedelic research, particularly those involving psilocybin, could benefit service members who are active on duty and veterans transitioning back to civilian life.

“President Trump opened up a world of possibility for treating Veterans and others with mental health conditions, and VA is proud to be part of this important work,” said VA Secretary Doug Collins. “Today’s MOU ensures effective cooperation with HHS as we try to turn research into life-changing treatment.”

Also read: Under HHS's 'Make Hospital Food Healthier' Pledge, Trump Administration Pushes Hospitals To Offer Healthier Food

Initiative To Accelerate Treatments For Mental Illnesses

The initiative was accelerated this year in April when President Donald Trump signed an executive order directing federal agencies to ramp up research, regulatory review, and appropriate patient access ways for psychedelic medicines targeting serious mental illnesses.

According to the White House, the goal is to expand the scope of scientific research while ensuring safety and regulatory requirements, rather than recklessly legalizing psychedelic drugs for general medical use.

Most psychedelic compounds, including psilocybin, MDMA, and ibogaine, remain classified as Schedule I substances under federal law.

Also read: As Part Of Trump’s Great American Recovery Initiative, US Announces 281 Million Funding To Tackle Addiction

Mental Health Challenges Faced By Veterans

Mental health challenges remain one of the most pressing issues U.S. veterans face after their military service. They are prioritised because they face a disproportionately high burden of PTSD, depression, suicide, and traumatic brain injury among former service members.

While conventional treatments, including antidepressants and psychotherapy, help many patients, a substantial number do not achieve lasting relief.

Researchers hope psychedelic-assisted therapy, administered under carefully supervised clinical settings alongside psychotherapy, may offer another option for people who are still struggling despite existing treatments.

Growing Interest In Psychedelic Medicine

The interest in psychedelic medicine has grown rapidly over the past decade. Studies have suggested that MDMA-assisted psychotherapy may help alleviate PTSD symptoms in some patients, while psilocybin-assisted therapy has shown promise for treatment-resistant depression in clinical trials.

These therapies differ from recreational drug use because they involve carefully screened patients, controlled doses, trained therapists, and structured treatment plan and follow-up sessions.

The World Health Organization (WHO) has validated El Salvador for eliminating trachoma, the world's leading infectious cause of blindness, as a public health problem.

El Salvador is the first country in Central America and the second in the Americas to achieve this milestone.

"I congratulate El Salvador on this remarkable achievement. It is a testament to the power of political commitment, strategic investment, and community engagement," said WHO Director-General Dr Tedros Adhanom Ghebreyesus.

"El Salvador's success is a vital step towards our global target of eliminating trachoma worldwide by 2030 and a clear signal that a healthier, more equitable future is within reach," he added.

El Salvador's Journey To Trachoma Elimination

Also read: US Appeals Court Revives Over 500 Tylenol Lawsuits Over Autism Claims

Between 2023 and 2026, El Salvador conducted targeted assessments in communities identified as at higher environmental and social risk. The surveys found no evidence of active trachoma transmission.

As per the WHO, "no cases of active disease were detected in children, and no adults were found to have advanced trachoma capable of causing blindness". These findings confirmed that trachoma is no longer a public health problem in the country, the UN health agency said.

El Salvador's achievement was supported by a coordinated approach that included:

• Strengthening primary healthcare services
• Improving water, sanitation and hygiene (WASH)
• Expanding eye health services, including adult vision screening
• Collaboration between government agencies, communities and international partners

The country has also established trained health personnel, integrated surveillance systems and the capacity to detect and treat trichiasis—the advanced stage of trachoma in which eyelashes turn inward and can lead to blindness.

What Is Trachoma?

Trachoma is a bacterial eye infection caused by Chlamydia trachomatis. It can spread from person to person through contaminated fingers, fomites and flies that could come into contact with discharge from the eyes or nose of an infected person.

Environmental risks like poor hygiene, overcrowded households, and inadequate access to water and sanitation facilities can also lead to trachoma.

Repeated infections can scar the inner eyelid, causing the eyelashes to turn inward—a condition known as trichiasis. Without treatment, the eyelashes scratch the surface of the eye, potentially leading to irreversible blindness.

Read More: Wegovy More Likely To Cause Rare Blindness Than Ozempic And Other Similar Drugs, Recent Study Finds

Trachoma Still Persists In Parts Of The Americas

Although El Salvador has eliminated trachoma as a public health problem, the disease remains endemic in rural and remote areas of Brazil, Colombia, Guatemala and Peru.

WHO recommends that countries maintaining elimination continue surveillance and ensure access to quality eye care services to prevent the disease from re-emerging.

WHO Criteria For Elimination

WHO defines elimination of trachoma as a public health problem based on three key criteria:

• Trichiasis prevalence of less than 0.2% among people aged 15 years and older.
• Active trachoma (trachomatous inflammation–follicular) prevalence of less than 5% among children aged 1–9 years in every previously endemic district.
• A functioning health system capable of identifying and managing new trichiasis cases.

With this achievement, El Salvador joins 64 countries worldwide that have been validated by WHO for eliminating at least one neglected tropical disease. Seven of these countries are in the Americas.